Join us for the next seminar series on April 28, 3:00pm EST.
The comparative safety of acid suppressant drugs: is there an increased risk of gastrointestinal malignancies?
Acid suppressant drugs, which include proton pump inhibitors (PPIs) and histamine-2 receptor antagonists (H2RAs) are among the most commonly prescribed medications worldwide. However, there have been concerns that these drugs are overprescribed, either in individuals without an underlying indication for use, or for longer durations than necessary. This overuse is especially concerning in light of safety risks that have been associated with the use of acid suppressant drugs, including a potential increased risk of gastrointestinal malignancies. I will present two real-world drug safety studies using data from the United Kingdom to address this open safety concern.
- To determine whether the use of PPIs, when compared with the use of H2RAs, is associated with an increased risk of incident gastric cancer
- To determine whether new users of PPIs are at an increased risk of colorectal cancer compared to new users of H2RAs
- Abrahami, Devin, et al. “Proton pump inhibitors and risk of gastric cancer: population-based cohort study.” Gut 71.1 (2022): 16-24
- Abrahami, Devin, et al. “Proton pump inhibitors and risk of colorectal cancer.” Gut 71.1 (2022): 111-118
Register in advance for this webinar:
After registering, you will receive a confirmation email containing information about joining the meeting.